TL;DR: ⚪ Clean null — iloprost did not improve organ dysfunction even in a biomarker-selected (severe endotheliopathy) septic shock subgroup, though dose/timing limitations were flagged by reviewers.
1. Publication
- Title: Iloprost and Organ Dysfunction in Adults With Septic Shock and Endotheliopathy: A Randomized Clinical Trial
- Acronym: None assigned
- Year & Journal: JAMA Network Open, published September 11, 2024 (7(9):e2432444)
- Citation: Bestle MH, Stensballe J, Lange T, et al. JAMA Netw Open. 2024;7(9):e2432444. doi:10.1001/jamanetworkopen.2024.32444
2. Context & Rationale
Background: Soluble thrombomodulin (sTM) is a marker of endotheliopathy; high plasma sTM (>10 ng/mL) is associated with worse organ dysfunction and mortality in septic shock. Iloprost, a prostacyclin analog, may improve endothelial function, offering a mechanistically targeted approach to a biomarker-defined subgroup.
Research Question/Hypothesis: In ICU adults with septic shock and severe endotheliopathy (sTM >10 ng/mL), does a 72-hour iloprost infusion reduce mean daily SOFA score compared with placebo?
3. Design & Methods
- Study Type: Multicenter, randomized, placebo-controlled, blinded (masked) RCT
- Setting & Centers: Denmark (Copenhagen University Hospital network)
- Population: 278 ICU adults with septic shock and endotheliopathy (sTM >10 ng/mL); screening performed up to 12h after septic shock diagnosis
- Intervention: Iloprost, 1 ng/kg/min infusion for 72 hours
- Comparator: Placebo
- Blinding: Masked (double-blind)
- Statistical Power & Follow-Up: Primary: mean daily SOFA score during infusion.
4. Key Results
278 patients randomized.
Outcome | Iloprost | Placebo | Notes |
Mean daily SOFA score (primary) | Similar | Similar | No significant difference — clear null |
5. Internal Validity Assessment
Double-blind, adequately sized (278-patient) RCT with biomarker-defined enrichment. Overall: Moderate-to-strong — clean null result; however, independent commentary (Medscape) flagged the low iloprost dose (1 ng/kg/min) and the up-to-12h screening delay after shock diagnosis as potential limitations that may have attenuated any true treatment effect.
6. External Validity Assessment
Danish, biomarker-selected (sTM>10) septic shock population — directly representative of the specific endotheliopathy-defined subgroup, though the biomarker threshold itself limits generalizability to broader septic shock.
7. Strengths & Limitations
Strengths: Double-blind design; biomarker-enriched population targeting a mechanistically plausible subgroup; addresses a genuine gap in endothelial-directed sepsis therapy.
Limitations: Low iloprost dose per independent critique; delayed screening window (up to 12h) may have missed the optimal treatment window; single-country trial.
8. Interpretation & Practice Impact
Does not support iloprost infusion for improving organ dysfunction in septic shock with severe endotheliopathy, even in this biomarker-selected population — per the authors' own conclusion, iloprost is unlikely to improve outcomes in this population as dosed.
9. Controversies & Subsequent Evidence
An accompanying review ("Prostacyclin for Patients with Septic Shock: Promise, Progress, and Perspective") situates this trial within the broader, still-unresolved prostacyclin-in-sepsis literature, describing the related I-MICRO trial as "well conducted and reported" alongside this null iloprost finding — suggesting dose and timing questions remain open for future prostacyclin-pathway trials.
10. Summary & Executive Takeaway
Summary: This Danish double-blind RCT randomized 278 ICU patients with septic shock and severe endotheliopathy (sTM>10 ng/mL) to a 72-hour iloprost infusion (1 ng/kg/min) or placebo. Mean daily SOFA scores were similar between groups — a clear null result.
Overall Takeaway: Iloprost, even in a biomarker-selected endotheliopathy subgroup, does not improve organ dysfunction in septic shock at the dose and timing tested — though independent critique suggests dose/timing limitations mean this should not be considered a definitive end to endothelial-directed prostacyclin therapy research.
11. Bibliography
- Johansen ME, Johansson PI, Ostrowski SR, et al. Profound endothelial damage predicts impending organ failure and death in sepsis.
- Bestle MH, et al. Efficacy and safety of iloprost in septic shock-induced endotheliopathy: protocol. Acta Anaesthesiol Scand. 2020;64(5):705-711.